The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

3 May 2012 07:00

RNS Number : 6214C
Sopheon PLC
03 May 2012
 



Embargoed Release: 07:00hrs Thursday 3 May 2012

 

 

SOPHEON PLC

("Sopheon" or the "Company")

 

INTERIM MANAGEMENT STATEMENT

 

Sopheon plc, the international provider of software and services that improve the financial return from innovation and product development investments, announces its first interim management statement for the period from1 January 2012 to the date of this announcement, in line with the requirements of the EU Transparency Directive.

 

After the good start to the year which we highlighted in our 2011 results announcement, sales activities have continued to increase. Highlights for the year to date include:

 

14 new and extension license orders achieved, in addition to a number of substantial services engagements. Business from existing customers remains strong, and a number of new customers have also been won. Revenue visibility for the full year from contracted business and recurring revenue streams now stands above £6.5 million, compared to £6.1 million a year ago. We expect to close additional business in the second quarter from a mix of new and existing customers. Services business remains strong, already absorbing new hires made in the first quarter.

  

We advanced our market presence across Europe with the addition of two sales representatives, building on the recent appointment of Jim Conroy as our European commercial leader. These additional hires were made with due caution given that global markets have not yet regained their poise and accurate prediction of the timing and value of individual sales remains challenging.

 

A major product milestone was achieved with the release of Accolade 8.0, the latest version of our flagship software solution. This landmark release offers enhanced support for project portfolio management and collaboration, integration with Microsoft's SharePoint® technology and a mobile application designed for use with iPhone® and iPad®.devices. Other features deepen our software's ease-of-configuration and ease-of-use. Reflecting input from a number of high-profile customers, we believe Accolade 8.0 sets a new standard for agility in managing innovation.

 

On the corporate front, Sopheon is actively considering the transfer of its listing from the regulated market operated by NYSE Euronext in Amsterdam to its exchange-regulated market, NYSE Alternext in Amsterdam. This would enable the Company to benefit from certain tax exemptions which the Board believe will make it more attractive to specialist investment funds. It will also reduce the regulatory burden associated with a fully regulated market like NYSE Euronext which the Board and its advisers consider to be disproportionate to a company of Sopheon's size and resources. NYSE Alternext is a well-recognized market with over 180 companies listed, representing a combined market capitalization of €5.9 billion. Since NYSE Alternext uses the same trading platform as NYSE Euronext, no change is expected to the mechanisms by which shareholders can buy and sell Sopheon shares. A resolution will be put to shareholders in connection with this proposed transfer at the forthcoming Annual General Meeting of the company, to be held at the offices of Squire Sanders (UK) LLP, 7 Devonshire Square, London EC2M 4YH on 13 June 2012 at 11:00am.  

 

Accolade® is a registered trademark of Sopheon plc. SharePoint® is a registered trademark of Microsoft Corporation. iPhone® and iPad®

are registered trademarks of Apple®

For further information contact:

 

Barry Mence, Chairman

Sopheon plc

Tel : + 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

Tel : + 44 (0) 1483 685 735

Charlotte Stranner/ Henrik Persson/ Victoria Bates

finnCap

Tel: +44 (0) 20 7600 1658

Guy McDougall/Heather Armstrong

Newgate Threadneedle

Tel : + 44 (0) 20 7653 9850

Claire Verhagen

Citigate First Financial

Tel : + 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) is an international provider of software and services. Sopheon's solutions structure, align and manage innovation processes to help organizations generate more revenues and profits from new products. Sopheon's solutions are used by industry leaders throughout the world, including BAE Systems, BASF, Corning, Electrolux, Honeywell, Novartis and SABMiller. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEAKSAEDXAEFF
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.